Novartis Ag (NVS) EPS (Basic) Growth (1y) (2010 - 2026)
Novartis Ag (NVS) EPS (Basic) Growth (1y) (2010 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Basic) Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 645.88 Bn | 625.12 Bn | 17.26 Bn | -0.10% |
| 2 | AbbVie | 463.46 Bn | 456.89 Bn | 12.70 Bn | 284.05% |
| 3 | Merck | 367.92 Bn | 360.78 Bn | 12.21 Bn | -130.68% |
| 4 | Novartis Ag | 297.71 Bn | 290.02 Bn | 11.24 Bn | -92.05% |
| 5 | Astrazeneca | 255.55 Bn | 250.65 Bn | 12.86 Bn | 2.26% |
| 6 | Amgen | 234.52 Bn | 220.53 Bn | 7.24 Bn | 65.24% |
| 7 | Gilead Sciences | 178.22 Bn | 175.04 Bn | 6.22 Bn | -636.10% |
| 8 | Pfizer | 158.57 Bn | 146.88 Bn | 10.94 Bn | -108.11% |
| 9 | Gsk | 105.32 Bn | 101.15 Bn | 8.24 Bn | -69.49% |
| 10 | Sanofi | 54.20 Bn | 46.82 Bn | 10.79 Bn | -90.87% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -92.05% |
| Jun 30, 2025 | 4.99% |
| Dec 31, 2024 | -2.86% |
| Jun 30, 2024 | -17.53% |
| Dec 31, 2023 | -17.42% |
| Sep 30, 2023 | 7.67% |
| Jun 30, 2023 | -13.06% |
| Mar 31, 2023 | -100.00% |
| Dec 31, 2022 | -9.79% |
| Sep 30, 2022 | -82.13% |
| Jun 30, 2022 | 18.82% |
| Mar 31, 2022 | 146.53% |
| Dec 31, 2021 | 21.35% |
| Sep 30, 2021 | -99.99% |
| Jun 30, 2021 | 2.49% |
| Mar 31, 2021 | 7,261,443.93% |
| Dec 31, 2020 | 2.65% |
| Sep 30, 2020 | 400,508.67% |
| Jun 30, 2020 | 5.60% |
| Mar 31, 2020 | -60.65% |